These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34851520)

  • 1. [An antipsychotic without dopamine receptor blockade?].
    Spoelstra SK; Bruggeman R; Knegtering H
    Tijdschr Psychiatr; 2021; 63(11):804-809. PubMed ID: 34851520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
    Højlund M; Correll CU
    Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT
    Saarinen M; Mantas I; Flais I; Ågren R; Sahlholm K; Millan MJ; Svenningsson P
    Neuropsychopharmacology; 2022 Dec; 47(13):2319-2329. PubMed ID: 36100653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
    Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
    N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
    Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
    J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.
    Siafis S; Chiocchia V; Macleod MR; Austin C; Homiar A; Tinsdeall F; Friedrich C; Ramage FJ; Kennett J; Nomura N; Maksym O; Rutigliano G; Vano LJ; McCutcheon RA; Gilbert D; Ostinelli EG; Stansfield C; Dehdarirad H; Juma DO; Wright S; Simple O; Elugbadebo O; Tonia T; Mantas I; Howes OD; Furukawa TA; Milligan L; Moreno C; Elliott JH; Hastings J; Thomas J; Michie S; Sena ES; Seedat S; Egger M; Potts J; Cipriani A; Salanti G; Leucht S
    Wellcome Open Res; 2024; 9():182. PubMed ID: 39036710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
    Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
    Newman-Tancredi A; Kleven MS
    Psychopharmacology (Berl); 2011 Aug; 216(4):451-73. PubMed ID: 21394633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
    Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.
    Celada P; Bortolozzi A; Artigas F
    CNS Drugs; 2013 Sep; 27(9):703-16. PubMed ID: 23757185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
    Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
    Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of SEP-363856 within TAAR1 and the 5HT
    Nair PC; Miners JO; McKinnon RA; Langmead CJ; Gregory KJ; Copolov D; Chan SKW; Bastiampillai T
    Mol Psychiatry; 2022 Jan; 27(1):88-94. PubMed ID: 34376825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
    Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.